1. Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017
- Author
-
Carlien A. M. Bennebroek, F.T. Kerkhoff, Frank A.M. van den Dungen, Robert P.G. Feenstra, Mark A. H. B. M. van der Hoeven, Cathrien A. Eggink, Elke Kraal‐Biezen, Wes Onland, Nicoline E. Schalij-Delfos, Enrico Lopriore, Floris Groenendaal, Laurentius J. van Rijn, Koen P. Dijkman, Noël J.C. Bauer, Kasia Trzcionkowska, Frank A B A Schuerman, Elsbeth S.M. Voskuil‐Kerkhof, Arno van Heijst, Ruben S G M Witlox, Huibert J. Simonsz, Victor W. Renardel de Lavalette, Peter H. Dijk, J.U.M. Termote, Wouter Vehmeijer, René F. Kornelisse, Oogheelkunde, MUMC+: MA UECM Oogartsen MUMC (9), Kindergeneeskunde, RS: GROW - R4 - Reproductive and Perinatal Medicine, MUMC+: MA Medische Staf Kindergeneeskunde (9), Pediatrics, Ophthalmology, Graduate School, Neonatology, ARD - Amsterdam Reproduction and Development, Pediatric surgery, and Amsterdam Reproduction & Development (AR&D)
- Subjects
Male ,Vascular Endothelial Growth Factor A ,Pediatrics ,Visual Acuity ,Angiogenesis Inhibitors ,Sensory disorders Donders Center for Medical Neuroscience [Radboudumc 12] ,chemistry.chemical_compound ,0302 clinical medicine ,retinopathy of prematurity ,Netherlands ,OUTCOMES ,Laser Coagulation ,infants born ,Absolute number ,treatment ,Incidence ,Retinal detachment ,Gestational age ,Retinopathy of prematurity ,General Medicine ,Treatment characteristics ,Bevacizumab ,Intravitreal Injections ,Original Article ,Female ,guideline ,medicine.medical_specialty ,laser photocoagulation ,Birth weight ,Gestational Age ,03 medical and health sciences ,medicine ,Humans ,Intravitreal bevacizumab ,Retrospective Studies ,business.industry ,Infant, Newborn ,Infant ,Retinal ,Original Articles ,medicine.disease ,eye diseases ,Ophthalmology ,chemistry ,EXTREME ,030221 ophthalmology & optometry ,sense organs ,business ,oxygen ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Contains fulltext : 235444.pdf (Publisher’s version ) (Open Access) PURPOSE: Compare patients treated for Retinopathy of Prematurity (ROP) in two consecutive periods. METHODS: Retrospective inventory of anonymized neonatal and ophthalmological data of all patients treated for ROP from 2010 to 2017 in the Netherlands, subdivided in period (P)1: 1-1-2010 to 31-3-2013 and P2: 1-4-2013 to 31-12-2016. Treatment characteristics, adherence to early treatment for ROP (ETROP) criteria, outcome of treatment and changes in neonatal parameters and policy of care were compared. RESULTS: Overall 196 infants were included, 57 infants (113 eyes) in P1 and 139 (275 eyes) in P2, indicating a 2.1-fold increase in ROP treatment. No differences were found in mean gestational age (GA) (25.9 ± 1.7 versus 26.0 ± 1.7 weeks, p = 0.711), mean birth weight (791 ± 311 versus 764 ± 204 grams, p = 0.967) and other neonatal risk factors for ROP. In P2, the number of premature infants born
- Published
- 2021